Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 42% Improvement Relative Risk HCQ for COVID-19  Wiseman et al.  META ANALYSIS c19hcq.org Favors HCQ Favors control

Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data

Wiseman et al., medRxiv, doi:10.1101/2020.11.29.20235218
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
6th independent analysis showing efficacy from the Boulware PEP trial. This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).
42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97], p=0.044, for the original trial 3 day specification.
7 meta analyses show significant improvements with hydroxychloroquine for mortality Landsteiner de Sampaio Amêndola, Risch, Risch (B), Stricker, hospitalization Landsteiner de Sampaio Amêndola, recovery Prodromos, combined death/hospitalization/cases Ladapo, and cases García-Albéniz.
Currently there are 8 HCQ for COVID-19 post-exposure prophylaxis studies, showing 46% lower mortality [-80‑84%], 16% lower hospitalization [-69‑58%], and 25% fewer cases [-0‑43%].
risk of case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wiseman et al., 2 Dec 2020, preprint, 4 authors.
This PaperHCQAll
Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data
PhD, MRPharmS David M Wiseman, MD Pierre Kory, PhD, MB Samir A Saidi, PhD. d Dan Mazzucco
doi:10.1101/2020.11.29.20235218
BACKGROUND: A key trial (NCT04308668) of post-exposure prophylaxis found hydroxychloroquine-associated (HCQ) reductions of Covid-19 by 17% overall and 31% to 49% in subgroups. To understand these trends, we reanalyzed the dataset. METHODS: Our protocol conformed to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). We compared the incidence of Covid-19 after HCQ or placebo, stratifying by intervention lag, age, and gender. RESULTS: Newly requested data missing from the dataset revealed that 52% and 19% of subjects received medication 1-2 days after intended and assumed overnight delivery or four-day intervention lag respectively. After re-analysis, we found reduced HCQ-associated incidence of Covid-19 with Early (up to 3 days post-exposure) (RR 0.58, 95%CI 0.35 -0.97; p=0.044; NNT 14.5) but not Late (RR 1.22, 95%CI 0.72 -2.04) prophylaxis. We found a significant HCQ-associated Covid-19 reduction in subjects 18 to 45 years old with Early (RR 0.54, 95%CI 0.29-0.97; p=0.0448, NNT 11.5) but not Late (RR 1.02, 95%CI 0.55-1.89) prophylaxis, attenuated in older subjects (RR 0.75, 95%CI 0-27-2.05) and by co-morbidities. Although, we did not detect effects of gender, folate, zinc, or ascorbate, confounding effects cannot be excluded. CONCLUSIONS: Using novel data and prospective re-analysis, hydroxychloroquine, in an age-dependent manner, was associated with reduced Covid-19 compatible illness when supplied for post-exposure prophylaxis between 1 and 3 days after high-or moderate-risk exposure, at higher loading and maintenance doses than in similar studies. The original study conclusions are controverted, and our finding warrants prospective confirmation.
Conflicts of Interest The sponsor is entirely responsible for its design and conduct. The sponsor and principal investigator have no financial or other conflicts of interest in the subject matter of this study. DMW is the president of Synechion, Inc. and KevMed, LLC, providing services for the medical industry and marketing medical products, respectively, outside of the area of this work. See ICMJE forms for further details. DM is the president of ZSX Medical, LLC. developing surgical devices and a Principal at Third Eye Associates, a technical consulting company. PK and SAS report no conflicts. Data Sharing Microsoft Excel files will be available on reasonable request up to one year after publication to qualified investigators subject to an agreed upon data sharing agreement. The source dataset is available from the original authors.
References
Al-Kofahi, Jacobson, Boulware, Matas, Kandaswamy et al., Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness, Clinical pharmacology and therapeutics, doi:10.1002/cpt.1874
Avidan, Dehbi, Delany-Moretlwe, Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMc2023617
Barnabas, Brown, Bershteyn, Karita, Johnston et al., Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial, Ann Intern Med, doi:10.7326/m20-6519
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Carlucci, Ahuja, Petrilli, Rajagopalan, Jones et al., Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients, medRxiv, doi:10.1101/2020.05.02.20080036
Chan, Tetzlaff, Gotzsche, Altman, Mann et al., SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials, BMJ
Cohen, Hydroxychloroquine for the Prevention of Covid-19 -Searching for Evidence, N Engl J Med, doi:10.1056/NEJMe2020388
Cook, Delong, Murray, Vollmer, Heagerty, Statistical lessons learned for designing cluster randomized pragmatic clinical trials from the NIH Health Care Systems Collaboratory Biostatistics and Design Core, Clinical trials, doi:10.1177/1740774516646578
Dhibar, Arora, Kakkar, Singla, Mohindra et al., Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106224
Ejima, Kim, Ludema, Bento, Iwanami et al., Estimation of the incubation period of COVID-19 using viral load data, medRxiv, doi:10.1101/2020.06.16.20132985
Fda, FDA Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems
Frontera, Rahimian, Yaghi, Liu, Lewis et al., Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study, doi:10.21203/rs.3.rs-94509/v1
Guzman-Prado, Retraction of Studies on Potential Drug Therapies for COVID-19: A Call for Reliability and Scientific Integrity, The American journal of cardiology, doi:10.1016/j.amjcard.2020.06.061
Hinton, Food and Drug Administration
Holford, Carr, Jovic, Ali, Whitaker et al., Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19, Nutrients, doi:10.3390/nu12123760
Karunajeewa, Hydroxychloroquine for coronavirus: how not to repurpose a drug during a pandemic, Internal medicine journal, doi:10.1111/imj.15064
Lofgren, Nicol, Bangdiwala, Pastick, Okafor et al., Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19, Open Forum Infect Dis, doi:10.1093/ofid/ofaa500
Luco, Hydroxychloroquine as Post-Exposure Prophylaxis for Covid-19: Why simple data analysis can lead to the wrong conclusions from well-designed studies, Trends Med
Mitjà, Corbacho-Monné, Ubals, Alemany, Suñer et al., A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2021801
Mudge, Baker, Edge, Houlahan, Setting an optimal alpha that minimizes errors in null hypothesis significance tests, PLoS One, doi:10.1371/journal.pone.0032734
Nicol, Boulware, Rajasingham, Reply to author, Clin Infect Dis, doi:10.1093/cid/ciaa1809
Okafor, Pastick, Rajasingham, Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply, N Engl J Med, doi:10.1056/NEJMc2023617
Quintó, Morales-Asencio, González, Menéndez, Is there sufficient scientific evidence to rule out the use of hydroxychloroquine for postexposure prophylaxis of COVID-19? OSF Preprints, doi:10.31219/osf.io/d9prq
Rajasingham, Bangdiwala, Nicol, Skipper, Pastick et al., Hydroxychloroquine as preexposure prophylaxis for COVID-19 in healthcare workers: a randomized trial, Clin Infect Dis, doi:10.1093/cid/ciaa1571
Saag, Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science, JAMA, doi:10.1001/jama.2020.22389
Skipper, Pastick, Engen, Bangdiwala, Abassi et al., Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial, Ann Intern Med, doi:10.7326/M20-4207
Smith, Mendoza, Smith, Dobesh, Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic, medRxiv, doi:10.1101/2021.05.28.21258012
Tan, Wong, Leo, Toh, Does incubation period of COVID-19 vary with age? A study of epidemiologically linked cases in Singapore, Epidemiology and infection, doi:10.1017/S0950268820001995
Wang, Lagakos, Ware, Hunter, Drazen, Statistics in medicine--reporting of subgroup analyses in clinical trials, N Engl J Med, doi:10.1056/NEJMsr077003
Watanabe, Efficacy of Hydroxychloroquine as Prophylaxis for Covid-19
White, Watson, Hoglund, Chan, Cheah et al., COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology, PLoS Med, doi:10.1371/journal.pmed.1003252
Wiseman, Arshad, Possible synergistic effects of hydroxychloroquine and steroids in COVID-19, time for a nuanced approach, of the International Society for Infectious Diseases, doi:10.1016/j.ijid.2020.07.064
Wiseman, Kory, Mazzucco, Ramesh, Zervos, Treatment and prevention of early disease before and after exposure to COVID-19 using hydroxychloroquine: A protocol for exploratory re-analysis of age and timenuanced effects: Update based on initial dataset review, medRxiv, doi:10.1101/2020.08.19.20178376
Yang, Liu, Shao, Yang, Xu et al., Hydroxychloroquine and Interferons for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances, J Clin Cell Immunol, doi:10.35248/2155-9899.20.11:596
Zahra, Heydari, Manica, Mehdi, Hassan et al., The Role of Folic Acid in the Management of Respiratory Disease Caused by COVID-19, doi:10.26434/chemrxiv.12034980.v1
Zuidgeest, Goetz, Groenwold, Van Thiel, Grobbee, Series: Pragmatic trials and real world evidence: Paper 1. Introduction, J Clin Epidemiol, doi:10.1016/j.jclinepi.2016.12.023
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit